Clinical Trial Update: Digoxin for Congenital Erythrocytosis Due to Up-Regulated Hypoxia Sensing [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial investigating digoxin for congenital erythrocytosis linked to up-regulated hypoxia sensing has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chuvash Polycythemia
• Congenital Erythrocytosis
• Erythrocytosis Due to Epas1 Mutation
• Erythrocytosis Due to Phd2 Mutation
• Erythrocytosis Due to Vhl Gene Mutation
• Familial Erythrocytosis
• Polycythemia

Drugs mentioned

• DIGOXIN (Digoxin)

Snippet

Sponsor: University of Illinois at Chicago | Conditions: Polycythemia; Familial, Erythrocytosis; Familial | Phase 1 | Status: WITHDRAWN